Why Is Kura Oncology Stock Skyrocketing Friday? - Kura Oncology ( NASDAQ:KURA )
On Thursday, the U.S. Food and Drug Administration granted full approval to Komzifti ( ziftomenib ) , developed by Kura Oncology Inc. ( NASDAQ:KURA ) and Kyowa Kirin Co., Ltd., for treating relapsed or refractory ( R/R ) acute myeloid leukemia ( AML ) with a susceptible NPM1 mutation.
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ ( ziftomenib ) , the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia - Kura Oncology ( NASDAQ:KURA )
- NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients - - Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rates at relapse - - FDA grants full approval of KOMZIFTI ahead of PDUFA target action date -
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ ( ziftomenib ) , the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
- NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation ...
Kura Oncology ( KURA ) Reports Q3 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -49.12% and -75.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Kura Oncology Reports Third Quarter 2025 Financial Results
- New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November ...
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
- Data to be featured in two oral presentations on December ...
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting - Kura Oncology ( NASDAQ:KURA )
- Data to be featured in two oral presentations on December 8, 2025 - - Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use -
Why Is Kura Oncology Stock Surging Friday? - Kura Oncology ( NASDAQ:KURA )
Kura Oncology, Inc. ( NASDAQ:KURA ) shares rose Friday after the biotechnology firm confirmed a $30 million milestone payment from its collaboration with Kyowa Kirin.
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
- Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical ...
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor ( FTI ) Programs at the 2025 European Society for Medical Oncology ( ESMO ) Congress - Kura Oncology ( NASDAQ:KURA )
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib's potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor ( FTI ) Programs at the 2025 European Society for Medical Oncology ( ESMO ) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on October 1, 2025, the Compensation ...
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia ( AML )
- Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in ...
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
- KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses ...
Kura Oncology to Participate in Upcoming Investor Conference
SAN DIEGO, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following ...
Kura Oncology to Participate in Upcoming Investor Conference - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor ...
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Analyst/Investor event showcases opportunities for KO-2806 ( darlifarnib ) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors ...
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types - Kura Oncology ( NASDAQ:KURA )
Analyst/Investor event showcases opportunities for KO-2806 ( darlifarnib ) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors ( TKIs ) Preliminary clinical data and KO-2806 development plans to be presented in October 2025 in conjunction ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation ...
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth - Syndax Pharmaceuticals ( NASDAQ:SNDX ) , Kura Oncology ( NASDAQ:KURA )
Q2 loss narrowed to $0.83 per share vs. $1.00 expected; sales hit $37.96 million vs. $26.78 million consensus. Revuforj revenue jumped 43% sequentially to $28.6 million, marking strong commercial momentum. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Entergy ( NYSE:ETR ) , AptarGroup ( NYSE:ATR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Brent Bracelin initiated coverage on HubSpot, Inc.
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program - Kura Oncology ( NASDAQ:KURA )
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Kura ...
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies ...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor ...
Evolv Technologies, Precigen, Hesai Group And Other Big Stocks Moving Higher On Friday - Applied Optoelectronics ( NASDAQ:AAOI ) , Evolv Technologies ( NASDAQ:EVLV )
U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session following strong quarterly results.
Kura Oncology ( KURA ) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Kura ( KURA ) Revenue Drops 61%
Kura Oncology ( NASDAQ:KURA ) , a clinical-stage company specializing in precision cancer medicines, released its second quarter 2025 financial results on August 7, 2025. The headline news was a sharp miss on collaboration revenue, with $15.3 million ( GAAP ) reported versus analyst expectations ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the ...
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the ...
Kura Oncology to Report Second Quarter 2025 Financial Results - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, July 31, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, July 03, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2025, the Compensation ...
Is the Options Market Predicting a Spike in Kura Oncology Stock?
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, June 06, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation ...
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
- CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients ...
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
- New Drug Application based on positive results from the Phase 2 KOMET-001 trial ...
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June ...
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting - Kura Oncology ( NASDAQ:KURA )
- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd - - Encore presentation planned at EHA 2025 Congress - - Kura Oncology to host virtual investor event at 7:30pm ET / 4:30pm PT on June 2nd to discuss ...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in ...
Kura Oncology to Participate in Three Upcoming Investor Conferences - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, May 20, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three ...
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association ( EHA ) Congress
- Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June ...
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, May 06, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN DIEGO, May 02, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) ( Nasdaq: KURA ) , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee ...
Kura Oncology ( KURA ) Reports Q1 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -29.41% and 88.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST - Kura Oncology ( NASDAQ:KURA )
- Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure - - Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and imatinib-resistant GIST preclinical models -
Kura Oncology to Report First Quarter 2025 Financial Results - Kura Oncology ( NASDAQ:KURA )
SAN DIEGO, April 24, 2025 ( GLOBE NEWSWIRE ) -- Kura Oncology, Inc. ( the "Company" ) KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after ...
